GlassScriptPhysician profile
Danielle S Strauss
NPI 1336378736
$5,417.64
in general payments reported to CMS, 2019-2025
24 companies · $2,386 in 2025
The $2,386 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,138 · 2020: $162 · 2021: $162 · 2022: $107 · 2023: $478 · 2024: $986 · 2025: $2,386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,343 · Consulting Fee: $1,470 · Travel and Lodging: $36.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,343.33 |
| Consulting Fee | $1,469.56 |
| Travel and Lodging | $36.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $1,505.70 | 2025 | Vicryl, Ethilon |
| Pfizer INC. | $1,110.00 | 2019 | |
| Abbvie INC. | $518.01 | 2022-2025 | Ozurdex, Alphagan P, Durysta |
| Alcon Vision LLC | $245.97 | 2024-2025 | Clareon, Tryptyr, Rocklatan |
| Harrow Eye, LLC | $220.88 | 2024-2025 | Vevye, Iheezo, Triesence |
| Dompe US, INC. | $203.81 | 2024-2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $176.68 | 2024-2025 | Acthar |
| Allergan, INC. | $159.86 | 2019-2020 | |
| Eyepoint US, INC. | $157.10 | 2023 | |
| Incyte Corporation | $126.81 | 2021 | |
| Bausch & Lomb Americas INC. | $126.28 | 2023-2025 | Xipere, Visudyne, Miebo |
| Alimera Sciences, INC. | $114.27 | 2020-2024 | Yutiq, Iluvien |
| Tarsus Pharmaceuticals, INC. | $113.29 | 2024-2025 | Xdemvy |
| Amgen INC. | $111.73 | 2024 | Lumakras, Tepezza |
| Pharmacosmos Therapeutics INC. | $108.53 | 2024 | Monoferric |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $83.17 | 2023 | |
| Biotissue Holdings INC. | $62.02 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $55.42 | 2025 | Yutiq, Iluvien |
| Genentech USA, INC. | $45.23 | 2022-2023 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $45.18 | 2023 | Eylea |
| Novartis Pharmaceuticals Corporation | $43.43 | 2023 | |
| Oyster Point Pharma, INC. | $41.44 | 2025 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $22.79 | 2024 | |
| Apellis Pharmaceuticals, INC. | $20.04 | 2024 | Syfovre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Strauss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.